Nanotechnology solutions for infectious diseases in developing nations

Advanced Drug Delivery Reviews

Volumn 62, Issue 4-5, 2010, Pages 375-377

  Sosnik, Alejandro ^a   Amiji, Mansoor ^b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; POLYMER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG RESEARCH; EARLY DIAGNOSIS; EDITORIAL; EPIDEMIC; FUNDING; GOVERNMENT; HEALTH CARE COST; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; INCIDENCE; INFECTION; LIFESTYLE; MALARIA; NANOTECHNOLOGY; NEOPLASM; PATENT; PRIORITY JOURNAL; RETROVIRUS INFECTION; SOCIOECONOMICS; TUBERCULOSIS; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HUMANS; INFECTION CONTROL; NANOTECHNOLOGY;

EID: 76849113073     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.010     Document Type: Editorial

References (17)

1. http://www.cientifica.com. The nanoparticle drug delivery market. Press release September 2007.
2. MIT Institute Professor Robert Langer joins Accelrys NanoBiology Initiative scientific advisory committee, Accelrys, Inc. Press release, July 26th 2006.
3. Look M., Bandyopadhyay A., Blum J.S., and Fahmy T.M. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug Del. Rev. 62 (2010) 378-393 (this issue)
4. Chadwick S., Kriegel C., and Amiji M. Nanotechnology solutions for mucosal immunization. Adv. Drug Del. Rev. 62 (2010) 394-407 (this issue)
5. Tallury P., Malhotra A., Byrne L.M., and Santra S. Nanobioimaging and sensing of infectious diseases. Adv. Drug Del. Rev. 62 (2010) 424-437 (this issue)
6. Kaittanis C., Santra S., and Perez J.M. Emerging nanotechnology-based strategies for diagnosis of infectious diseases. Adv. Drug Del. Rev. 62 (2010) 408-423 (this issue)
7. Hauck T.S., Giri S., Gao Y., and Chan W.C.W. Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Adv. Drug Del. Rev. 62 (2010) 438-448 (this issue)
8. Lee W.G., Kim Y.-G., Chung B.G., Demirci U., and Khademhosseini A. Nano/microfluidics for diagnosis of infectious diseases in developing countries. Adv. Drug Del. Rev. 62 (2010) 449-457 (this issue)
9. das Neves J., Amiji M.M., Bahia M.F., and Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv. Drug Del. Rev. 62 (2010) 458-477 (this issue)
10. Gupta U., and Jain N.K. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv. Drug Del. Rev. 62 (2010) 478-490 (this issue)
11. Sharma P., and Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv. Drug Del. Rev. 62 (2010) 491-502 (this issue)
12. Sosnik A., Carcaboso A.M., Glisoni R.J., Moretton M.A., and Chiappetta D.A. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv. Drug Del. Rev. 62 (2010) 547-559 (this issue)
13. Santos-Magalhães N.S., and Furtado Mosqueira V.C. Nanotechnology applied to the treatment of malaria. Adv. Drug Del. Rev. 62 (2010) 560-575 (this issue)
14. Romero E., and Morilla M.J. Nanotechnological approaches against Chagas disease. Adv. Drug Del. Rev. 62 (2010) 576-588 (this issue)
15. Wong H.L., Chattopadhyay N., Wu X.Y., and Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Del. Rev. 62 (2010) 503-517 (this issue)
16. du Toit L.C., Pillay V., and Choonara Y.E. Nano-microbicides: Challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv. Drug Del. Rev. 62 (2010) 532-546 (this issue)
17. Gunaseelan S., Gunaseelan K., Deshmukh M., Zhang X., and Sinko P.J. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv. Drug Del. Rev. 62 (2010) 518-531 (this issue)